Predicting the probability of abnormal stimulated growth hormone response in children after radiotherapy for brain tumors.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this phase 2 clinical trial publication.

To develop a mathematical model utilizing more readily available measures than stimulation tests that identifies brain tumor survivors with high likelihood of abnormal growth hormone secretion after radiotherapy (RT), to avoid late recognition and a consequent delay in growth hormone replacement therapy.

Who Took Part

The abstract describes 106 children taking part.

By PubMed's age tags, the people studied were infants, young children, children and teenagers, both men and women.

The researchers analyzed 191 prospectively collected post-RT evaluations of peak growth hormone level (arginine tolerance/levodopa stimulation test), serum insulin-like growth factor 1 (IGF-1), IGF-binding protein 3, height, weight, growth velocity, and body mass index in 106 children and adolescents treated for ependymoma (n=72), low-grade glioma (n=28) or craniopharyngioma (n=6), who had normal growth hormone levels before RT.

How the Study Was Run

Normal level in this study was defined as the peak growth hormone response to the stimulation test≥7 ng/mL.

What Was Measured

The subject headings attached to it are Arginine, Biomarkers, Brain Neoplasms, Craniopharyngioma, Ependymoma, Feasibility Studies and Glioma.

What This Means in Plain Language

This is a phase 2 clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 106 children.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2012 (International journal of radiation oncology, biology, physics), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.